PE20030361A1 - Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas - Google Patents
Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activasInfo
- Publication number
- PE20030361A1 PE20030361A1 PE2002000742A PE2002000742A PE20030361A1 PE 20030361 A1 PE20030361 A1 PE 20030361A1 PE 2002000742 A PE2002000742 A PE 2002000742A PE 2002000742 A PE2002000742 A PE 2002000742A PE 20030361 A1 PE20030361 A1 PE 20030361A1
- Authority
- PE
- Peru
- Prior art keywords
- agents
- butyl
- alkyl
- methyl
- inhibiting agents
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title abstract 3
- -1 ETHYL PROPYL Chemical group 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical group [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10140169A DE10140169A1 (de) | 2001-08-22 | 2001-08-22 | Kombinationspräparate von 1,4-Benzothiepin-1,1-dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung |
| DE10142456A DE10142456A1 (de) | 2001-08-31 | 2001-08-31 | Kombinationspräparate von 1,4-Benzothiepin-1,1dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030361A1 true PE20030361A1 (es) | 2003-05-27 |
Family
ID=26009944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000742A PE20030361A1 (es) | 2001-08-22 | 2002-08-16 | Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20030158119A1 (https=) |
| EP (1) | EP1425018B1 (https=) |
| JP (1) | JP2005501861A (https=) |
| KR (1) | KR20040032937A (https=) |
| CN (1) | CN1655792A (https=) |
| AR (1) | AR035285A1 (https=) |
| AT (1) | ATE411802T1 (https=) |
| AU (1) | AU2002333373B2 (https=) |
| BR (1) | BR0212031A (https=) |
| CA (1) | CA2457976A1 (https=) |
| CO (1) | CO5560550A2 (https=) |
| DE (1) | DE50212937D1 (https=) |
| HN (1) | HN2002000235A (https=) |
| HR (1) | HRP20040171A2 (https=) |
| HU (1) | HUP0401318A3 (https=) |
| IL (1) | IL160474A0 (https=) |
| MA (1) | MA26317A1 (https=) |
| MX (1) | MXPA04001328A (https=) |
| NO (1) | NO20040702L (https=) |
| NZ (1) | NZ531293A (https=) |
| OA (1) | OA12654A (https=) |
| PA (1) | PA8553201A1 (https=) |
| PE (1) | PE20030361A1 (https=) |
| PL (1) | PL366851A1 (https=) |
| RS (1) | RS11104A (https=) |
| RU (1) | RU2297222C2 (https=) |
| TN (1) | TNSN04034A1 (https=) |
| UY (1) | UY27419A1 (https=) |
| WO (1) | WO2003018024A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| IL156445A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| AR035533A1 (es) | 2001-01-26 | 2004-06-02 | Schering Corp | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| EP1601668B1 (en) | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CA2517572C (en) | 2003-03-07 | 2011-12-13 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| JP2010509252A (ja) | 2006-11-14 | 2010-03-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用 |
| DE102006053637B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102006053636B4 (de) * | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
| DE102006053635B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| WO2013055609A1 (en) * | 2011-10-12 | 2013-04-18 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions that inhibit disproportionation |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CN104023727B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
| US20140275090A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| PL3923943T3 (pl) | 2019-02-12 | 2024-12-09 | Mirum Pharmaceuticals, Inc. | Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663336B1 (fr) * | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| IL127296A (en) | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| PL338013A1 (en) | 1997-07-16 | 2000-09-25 | Novo Nordisk As | Derivatives of condensed 1,2,4-thiadiazine, their production and application |
| CO4970713A1 (es) * | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| DE69911058T2 (de) * | 1998-12-23 | 2004-06-03 | G.D. Searle Llc, Chicago | Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| JP2002542245A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
| WO2000066585A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| DE60029446T2 (de) | 1999-06-18 | 2007-02-08 | Merck & Co., Inc. | Arylthiazolidindione und aryloxazolidindion-derivate |
| BR0012752A (pt) | 1999-07-29 | 2002-04-02 | Lilly Co Eli | Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina |
| HUP0202472A3 (en) * | 1999-09-01 | 2005-03-29 | Aventis Pharma Gmbh | Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments |
| AU5257401A (en) * | 2000-04-28 | 2001-11-12 | Asahi Chemical Ind | Novel bicyclic compounds |
| DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | MELANOCORTIN RECEPTOR AGONISTS |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
-
2002
- 2002-08-09 NZ NZ531293A patent/NZ531293A/en not_active IP Right Cessation
- 2002-08-09 WO PCT/EP2002/008908 patent/WO2003018024A1/de not_active Ceased
- 2002-08-09 PL PL02366851A patent/PL366851A1/xx not_active Application Discontinuation
- 2002-08-09 AT AT02796213T patent/ATE411802T1/de not_active IP Right Cessation
- 2002-08-09 BR BR0212031-3A patent/BR0212031A/pt not_active IP Right Cessation
- 2002-08-09 HR HR20040171A patent/HRP20040171A2/xx not_active Application Discontinuation
- 2002-08-09 OA OA1200400057A patent/OA12654A/en unknown
- 2002-08-09 KR KR10-2004-7002440A patent/KR20040032937A/ko not_active Ceased
- 2002-08-09 IL IL16047402A patent/IL160474A0/xx unknown
- 2002-08-09 CN CNA028163109A patent/CN1655792A/zh active Pending
- 2002-08-09 CA CA002457976A patent/CA2457976A1/en not_active Abandoned
- 2002-08-09 RU RU2004108119/15A patent/RU2297222C2/ru not_active IP Right Cessation
- 2002-08-09 RS YU11104A patent/RS11104A/sr unknown
- 2002-08-09 MX MXPA04001328A patent/MXPA04001328A/es active IP Right Grant
- 2002-08-09 EP EP02796213A patent/EP1425018B1/de not_active Expired - Lifetime
- 2002-08-09 AU AU2002333373A patent/AU2002333373B2/en not_active Ceased
- 2002-08-09 HU HU0401318A patent/HUP0401318A3/hu unknown
- 2002-08-09 DE DE50212937T patent/DE50212937D1/de not_active Expired - Lifetime
- 2002-08-09 JP JP2003522542A patent/JP2005501861A/ja active Pending
- 2002-08-16 PE PE2002000742A patent/PE20030361A1/es not_active Application Discontinuation
- 2002-08-20 UY UY27419A patent/UY27419A1/es unknown
- 2002-08-20 PA PA20028553201A patent/PA8553201A1/es unknown
- 2002-08-20 AR ARP020103125A patent/AR035285A1/es not_active Application Discontinuation
- 2002-08-20 HN HN2002000235A patent/HN2002000235A/es unknown
- 2002-08-22 US US10/225,841 patent/US20030158119A1/en not_active Abandoned
-
2003
- 2003-11-03 US US10/699,967 patent/US7179792B2/en not_active Expired - Lifetime
-
2004
- 2004-02-11 MA MA27524A patent/MA26317A1/fr unknown
- 2004-02-18 NO NO20040702A patent/NO20040702L/no not_active Application Discontinuation
- 2004-02-19 CO CO04014418A patent/CO5560550A2/es not_active Application Discontinuation
- 2004-02-20 TN TNP2004000034A patent/TNSN04034A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040171A2 (en) | 2004-10-31 |
| EP1425018A1 (de) | 2004-06-09 |
| WO2003018024A1 (de) | 2003-03-06 |
| DE50212937D1 (de) | 2008-12-04 |
| NO20040702L (no) | 2004-05-19 |
| AU2002333373B2 (en) | 2006-12-14 |
| ATE411802T1 (de) | 2008-11-15 |
| HUP0401318A3 (en) | 2008-03-28 |
| TNSN04034A1 (en) | 2006-06-01 |
| US20030158119A1 (en) | 2003-08-21 |
| MXPA04001328A (es) | 2004-05-05 |
| IL160474A0 (en) | 2004-07-25 |
| HN2002000235A (es) | 2003-02-18 |
| JP2005501861A (ja) | 2005-01-20 |
| BR0212031A (pt) | 2004-08-03 |
| CA2457976A1 (en) | 2003-03-06 |
| US7179792B2 (en) | 2007-02-20 |
| RS11104A (sr) | 2006-12-15 |
| CN1655792A (zh) | 2005-08-17 |
| OA12654A (en) | 2006-06-15 |
| EP1425018B1 (de) | 2008-10-22 |
| UY27419A1 (es) | 2003-04-30 |
| PA8553201A1 (es) | 2004-08-31 |
| RU2004108119A (ru) | 2005-04-10 |
| AR035285A1 (es) | 2004-05-05 |
| KR20040032937A (ko) | 2004-04-17 |
| NZ531293A (en) | 2005-08-26 |
| RU2297222C2 (ru) | 2007-04-20 |
| CO5560550A2 (es) | 2005-09-30 |
| HUP0401318A2 (hu) | 2004-10-28 |
| MA26317A1 (fr) | 2004-10-01 |
| US20040097424A1 (en) | 2004-05-20 |
| PL366851A1 (en) | 2005-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030361A1 (es) | Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas | |
| AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
| MXPA03011981A (es) | 3-fluoruro-pirrolidinas como agentes antidiabeticos. | |
| EE200100558A (et) | Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine | |
| PL315636A1 (en) | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives | |
| DE60142891D1 (de) | Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung | |
| CY1107391T1 (el) | Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
| AP9801169A0 (en) | N-hydroxy-B-sulfonyl propionamide derivatives. | |
| AU2003269327A1 (en) | Tetrahydroquinoline derivatives as crth2 antagonists | |
| FI963398A0 (fi) | Kielenalainen tai poskensisäinen farmaseuttinen koostumus | |
| NO914356L (no) | Mono n-substituerte 1,4,7,10-tetraazacyklododekanderivater, fremgangsmaater for fremstilling av dem og farmasoeytiskemidler som inneholder dem | |
| AU2505297A (en) | Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect | |
| HUT77627A (hu) | 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények | |
| HU9602695D0 (en) | Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments | |
| IL148874A0 (en) | Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them | |
| IL159412A0 (en) | A synergistic pharmaceutical combination for the prevention or treatment of diabetes | |
| TW200735864A (en) | Immediate release pharmaceutical formulation | |
| IL131216A0 (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| DE69525327D1 (de) | Anthracyclin-derivate | |
| ATE161178T1 (de) | Pyrazolpyridine für die behandlung der anämie | |
| EP0263506A3 (en) | Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative | |
| NZ510116A (en) | Tricyclic delta-3-piperidines as pharmaceuticals | |
| SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
| TR200001122T2 (tr) | Farmasötikler olarak bifenil türevleri. | |
| GEP20074100B (en) | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |